WO2020022891A3 - Biomarqueurs pour fibrillation auriculaire - Google Patents

Biomarqueurs pour fibrillation auriculaire Download PDF

Info

Publication number
WO2020022891A3
WO2020022891A3 PCT/NL2019/050480 NL2019050480W WO2020022891A3 WO 2020022891 A3 WO2020022891 A3 WO 2020022891A3 NL 2019050480 W NL2019050480 W NL 2019050480W WO 2020022891 A3 WO2020022891 A3 WO 2020022891A3
Authority
WO
WIPO (PCT)
Prior art keywords
suffering
atrial fibrillation
individual
methods
biomarkers
Prior art date
Application number
PCT/NL2019/050480
Other languages
English (en)
Other versions
WO2020022891A2 (fr
Inventor
Bianca Johanna Josephina Maria Brundel
Marit WIERSMA
Natasja Mireille Silvia DE GROOT
Deli ZHANG
Original Assignee
Stichting Vumc
Erasmus University Medical Center Rotterdam
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stichting Vumc, Erasmus University Medical Center Rotterdam filed Critical Stichting Vumc
Publication of WO2020022891A2 publication Critical patent/WO2020022891A2/fr
Publication of WO2020022891A3 publication Critical patent/WO2020022891A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne des procédés de typage d'un individu comme souffrant, ou risquant de souffrir, d'une fibrillation auriculaire, comprenant les étapes de fourniture d'un fluide corporel provenant dudit individu et de quantification d'un biomarqueur dans ledit fluide corporel. L'invention concerne en outre des procédés d'attribution d'une thérapie de référence à un individu qui est typé comme souffrant, ou présentant un risque de souffrir, d'une fibrillation auriculaire, selon les procédés de typage de l'invention, et une thérapie de référence destinée à être utilisée dans un procédé de traitement d'un individu qui est typé comme souffrant, ou risquant de souffrir, d'une fibrillation auriculaire, selon les procédés de l'invention.
PCT/NL2019/050480 2018-07-26 2019-07-24 Biomarqueurs pour fibrillation auriculaire WO2020022891A2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP18185834.1 2018-07-26
EP18185834 2018-07-26
EP18185850 2018-07-26
EP18185850.7 2018-07-26
EP19157444.1 2019-02-15
EP19157444 2019-02-15

Publications (2)

Publication Number Publication Date
WO2020022891A2 WO2020022891A2 (fr) 2020-01-30
WO2020022891A3 true WO2020022891A3 (fr) 2020-03-05

Family

ID=67667891

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2019/050480 WO2020022891A2 (fr) 2018-07-26 2019-07-24 Biomarqueurs pour fibrillation auriculaire

Country Status (1)

Country Link
WO (1) WO2020022891A2 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047558A2 (fr) * 2004-10-26 2006-05-04 The General Hospital Corporation Methodes de detection d'une fibrillation atriale et de troubles lies

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0450060A1 (fr) 1989-10-26 1991-10-09 Sri International Sequen age d'adn
US5846719A (en) 1994-10-13 1998-12-08 Lynx Therapeutics, Inc. Oligonucleotide tags for sorting and identification
US5750341A (en) 1995-04-17 1998-05-12 Lynx Therapeutics, Inc. DNA sequencing by parallel oligonucleotide extensions
GB9620209D0 (en) 1996-09-27 1996-11-13 Cemu Bioteknik Ab Method of sequencing DNA
GB9626815D0 (en) 1996-12-23 1997-02-12 Cemu Bioteknik Ab Method of sequencing DNA
US6969488B2 (en) 1998-05-22 2005-11-29 Solexa, Inc. System and apparatus for sequential processing of analytes
US6274320B1 (en) 1999-09-16 2001-08-14 Curagen Corporation Method of sequencing a nucleic acid
DE10021390C2 (de) 2000-05-03 2002-06-27 Juergen Olert Protektionslösung und Fixierverfahren für die Paraffinschnitt-Technik
US7057026B2 (en) 2001-12-04 2006-06-06 Solexa Limited Labelled nucleotides
US7138226B2 (en) 2002-05-10 2006-11-21 The University Of Miami Preservation of RNA and morphology in cells and tissues
US7414116B2 (en) 2002-08-23 2008-08-19 Illumina Cambridge Limited Labelled nucleotides
DK3002289T3 (en) 2002-08-23 2018-04-23 Illumina Cambridge Ltd MODIFIED NUCLEOTIDES FOR POLYNUCLEOTIDE SEQUENCE
FR2852392B1 (fr) 2003-03-12 2005-07-08 Inst Claudius Regaud Composition de fixation tissulaire
US8241573B2 (en) 2006-03-31 2012-08-14 Illumina, Inc. Systems and devices for sequence by synthesis analysis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047558A2 (fr) * 2004-10-26 2006-05-04 The General Hospital Corporation Methodes de detection d'une fibrillation atriale et de troubles lies

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
ALFONS E SCHÄFLER ET AL: "Overexpression of heat shock protein 60/10 in myocardium of patients with chronic atrial fibrillation", THE ANNALS OF THORACIC SURGERY, 1 January 2002 (2002-01-01), pages 767 - 770, XP055540602, Retrieved from the Internet <URL:https://www.annalsthoracicsurgery.org/article/S0003-4975(02)03830-4/pdf> [retrieved on 20190110], DOI: 10.1016/S0003-4975(02)03830-4 *
CHANGGONG WU ET AL: "Cytochrome c oxidase III as a mechanism for apoptosis in heart failure following myocardial infarction", AMERICAN JOURNAL OF PHYSIOLOGY. CELL PHYSIOLOGY., vol. 297, no. 4, 1 October 2009 (2009-10-01), US, pages C928 - C934, XP055540475, ISSN: 0363-6143, DOI: 10.1152/ajpcell.00045.2009 *
CHIARA TAURINO ET AL: "Gene expression profiling in whole blood of patients with coronary artery disease", CLINICAL SCIENCE., vol. 119, no. 8, 1 October 2010 (2010-10-01), GB, pages 335 - 343, XP055540501, ISSN: 0143-5221, DOI: 10.1042/CS20100043 *
CIRCULATION, vol. 136, no. Suppl. 1, 14 November 2017 (2017-11-14), SCIENTIFIC SESSIONS AND EXHIBITION OF THE AMERICAN-HEART-ASSOCIATION / RESUSCITATION SCIENCE SYMPOSIUM; ANAHEIM, CA, USA; NOVEMBER 11 -15, 2017, pages 17177, ISSN: 0009-7322(print) *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 14 November 2017 (2017-11-14), TREMBINSKI DOROTEE JULIA ET AL: "Sarrah is an Aging-Regulated Anti-Apoptotic Long Non-Coding RNA in Cardiomyocytes that Augments Recovery From Acute Myocardial Infarction", XP002795656, Database accession no. PREV201800710094 *
DI ZHAO: "049: Mitochondrial DNA Copy Number and Incident Atrial Fibrillation: The Atherosclerosis Risk in Communities Study (ARIC)", CIRCULATION, vol. 137, 29 June 2018 (2018-06-29), pages 1 - 2, XP055540145, DOI: 10.1161/cir *
JANIKA VIERECK ET AL: "Circulating Noncoding RNAs as Biomarkers of Cardiovascular Disease and Injury", CIRCULATION RESEARCH, vol. 120, no. 2, 20 January 2017 (2017-01-20), US, pages 381 - 399, XP055642545, ISSN: 0009-7330, DOI: 10.1161/CIRCRESAHA.116.308434 *
NICOLA SANDLER ET AL: "Mitochondrial DAMPs Are Released During Cardiopulmonary Bypass Surgery and Are Associated With Postoperative Atrial Fibrillation", HEART, LUNG AND CIRCULATION, vol. 27, no. 1, 1 January 2018 (2018-01-01), AMSTERDAM, NL, pages 122 - 129, XP055540318, ISSN: 1443-9506, DOI: 10.1016/j.hlc.2017.02.014 *
QIN DINGXIN ET AL: "Comparative effectiveness of antiarrhythmic drugs for rhythm control of atrial fibrillation", JOURNAL OF CARDIOLOGY, vol. 67, no. 5, 27 September 2015 (2015-09-27), pages 471 - 476, XP029501165, ISSN: 0914-5087, DOI: 10.1016/J.JJCC.2015.07.001 *
QIYING DAI ET AL: "Circulating long non-coding RNAs as biomarkers of acute myocardial infarction", NON-CODING RNA INVESTIGATION, vol. 1, 1 January 2017 (2017-01-01), pages 4 - 4, XP055642800, ISSN: 2522-6673, DOI: 10.21037/ncri.2017.08.03 *
YINGJIA XU ET AL: "Identification of long non-coding RNAs as novel biomarker and potential therapeutic target for atrial fibrillation in old adults", ONCOTARGET, vol. 7, no. 10, 8 March 2016 (2016-03-08), XP055642779, DOI: 10.18632/oncotarget.7514 *

Also Published As

Publication number Publication date
WO2020022891A2 (fr) 2020-01-30

Similar Documents

Publication Publication Date Title
WO2015111008A3 (fr) Biomarqueurs prédictifs de l&#39;atrophie musculaire, procédé et utilisation associés
WO2019158998A3 (fr) Détermination de parties de largeur de bande liées
WO2017214373A8 (fr) Procédés diagnostiques et thérapeutiques relatifs au cancer
MX365979B (es) Metodo de gestion de recursos, huesped y punto de extremo.
WO2017035176A8 (fr) Procédé de prévention ou de traitement de l&#39;obésité à l&#39;aide d&#39;un inhibiteur d&#39;emc10
EP3936509A4 (fr) Inhibiteur de fgfr4 kinase, son procédé de préparation et son utilisation
EP4000216C0 (fr) Méthode de génération de pseudonymes cryptographiques, système informatique, programme informatique et support lisible par ordinateur
WO2011103330A3 (fr) Nouvelle phosphorylation de la troponine cardiaque i utilisée comme un moniteur de lésion cardiaque
IL289847A (en) Method, device, and computer-readable medium for adaptive normalization of levels of analysis
WO2016066862A3 (fr) Méthode de prédiction du risque d&#39;obésité chez un sujet
EP3989496A4 (fr) Dispositif de détermination de politique, procédé de détermination de politique et programme
EP3964579A4 (fr) Méthode de prédiction de l&#39;efficacité d&#39;un traitement pour les hémoglobinopathies
EP3935904A4 (fr) Procédé et appareil de mappage de ressources de pdsch sur un spectre sans licence
WO2020022891A3 (fr) Biomarqueurs pour fibrillation auriculaire
EP3903879A4 (fr) Procédé de défibrillation, défibrillateur externe automatique et support lisible par ordinateur
WO2016131629A8 (fr) Élément de châssis, procédé de fabrication et d&#39;utilisation dudit élément de châssis
HUE062614T2 (hu) Kriptográfiai álnév leképezõ eljárás, számítógépes rendszer, számítógépes program és számítógéppel olvasható adathordozó
EP3914897A4 (fr) Système et procédé de déstratification par faisceau d&#39;ions, système de surveillance de point d&#39;extrémité et procédé associé
WO2015125098A3 (fr) Biomarqueurs du cancer du poumon et leurs procédés et leur kit de diagnostic
EP3502271A3 (fr) Biomarqueurs du sang pour l&#39;appendicite et procédés de diagnostic utilisant des biomarqueurs
WO2021041573A3 (fr) Biomarqueurs pour troubles neurodégénératifs
MX2022003889A (es) Metodos para determinar la sensibilidad a la terapia anti-factor de necrosis tumoral en el tratamiento de la psoriasis.
EP4070733A4 (fr) Système de détermination d&#39;état physique anormal, procédé de détermination d&#39;état physique anormal et programme informatique
EP3879887A4 (fr) Procédé et appareil permettant de déterminer une ressource temps-fréquence, puce et programme informatique
EP3901631A3 (fr) Marqueurs dans la prépuberté pour le prédiabète chez l&#39;enfant

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19755990

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19755990

Country of ref document: EP

Kind code of ref document: A2